The North America Emphysema Treatment Market would witness market growth of 5.2% CAGR during the forecast period (2022-2028).
Patients with emphysema may be helped with treatment to alleviate their shortness of breath and reduce the number of times they need to be hospitalized. Before beginning therapy, patients will have a pulmonary function test to see how much air they can blow out. The widespread smoking behavior of a huge percentage of the world's population is the primary driver propelling growth in the emphysema treatment industry. Now, quitting smoking is the treatment that the vast majority of patients choose.
Regarding treating emphysema, bronchodilators, corticosteroids, oxygen medicines, and other antibiotics such as erythromycin are in high demand throughout the world's markets. The development of new medications for the management of emphysema has resulted in enormous profits for the pharmaceutical and medical businesses. There is a significant increase in the number of new products and treatments entering the market, which might restrict worldwide expansion.
According to the Centers for Disease Control and Prevention (CDC), those diagnosed with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis, have difficulty breathing. Many millions more people suffer with COPD, but the disease has not been identified in their cases, and they are not receiving treatment. In 2019, the number of people living with chronic obstructive pulmonary disease in Canada was 2.0 million (COPD).
In addition, the Centers for Disease Control and Prevention (CDC) reports that about 40 million people in the United States continue to smoke cigarettes. At the same time, 3.08 million middle school and high school kids use at least one tobacco product, particularly electronic cigarettes. About 1,600 children and teenagers in the United States under the age of 18 try their first cigarette daily. About 400,000 people in the United States pass away prematurely due to smoking or exposure to second-hand smoke each year. As a consequence of all of these factors, it is anticipated that the prevalence of emphysema will increase across the countries in the area. Because of this, there is an increased need for the treatment of emphysema in the North American area.
The US market dominated the North America Emphysema Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,967.8 million by 2028. The Canada market is showcasing a CAGR of 7.6% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 6.6% during (2022 - 2028).
Based on Medication Type, the market is segmented into Bronchodilators, Steroids, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Emphysema Treatment Market is Predict to reach $6.05 Billion by 2028, at a CAGR of 6.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma Plc.
By Medication Type
By Distribution Channel
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 